Universal Ibogaine Inc.

Universal Ibogaine provides Bi-weekly Default Status Report on 2025 year-end filings and update on Restructuring process

Universal Ibogaine provides Bi-weekly Default Status Report on 2025 year-end filings and update on Restructuring process

Universal Ibogaine Provides Bi-weekly Default Status Report on 2025 Year-end Filings and Update on Restructuring Process

Universal Ibogaine advises further on application for Management Cease Trade Order

Universal Ibogaine Advises of Filing Application for Management Cease Trade Order

Universal Ibogaine Provides Corporate Update

Universal Ibogaine Announces Board Changes

Universal Ibogaine Announces Results of the Annual Meeting of Shareholders

Universal Ibogaine Inc. provides update on intent to file Clinical Trial Application with Health Canada and confirms securing of Ibogaine drug supply

Universal Ibogaine advises of appointment of two new Board Members

Universal Ibogaine advises of departure of CFO

Universal Ibogaine Advises of Debt Settlement with CEO and Resignation of a Member of its Board of Directors

Universal Ibogaine Advises of Debt Settlement Agreement and Update on Status of Cease Trade Order

Universal Ibogaine says 2023 will be pivotal year for the company and Canadians seeking ibogaine treatment

Universal Ibogaine closes private placement, announces potential C$5M offering of convertible debt securities and shares

Universal Ibogaine forms advisory board in support of mission to deliver medicalized ibogaine-centered addiction care

Universal Ibogaine poised for offering to complete planned ibogaine-based clinical trial application

Universal Ibogaine says Kelburn addiction recovery clinic to reopen on October 17, 2022

Universal Ibogaine targets October re-opening of Kelburn addiction treatment facility near Winnipeg

Universal Ibogaine retains co-founder Shayne Nyquvest as capital markets advisor